Transurethral photodynamic therapy in benign prostatic hyperplasia : a canine pilot study using benzoporphyrin derivative

Sugandh D. Shetty M.D.; James O. Peabody; Elsa R. Beck D.V.M.; Joseph C. Cerny M.D.; Mahul B. Amin; Anna M. Richter

doi:10.1117/12.350957

22 June 1999 Transurethral photodynamic therapy in benign prostatic hyperplasia : a canine pilot study using benzoporphyrin derivative

Sugandh D. Shetty M.D., James O. Peabody, Elsa R. Beck D.V.M., Joseph C. Cerny M.D., Mahul B. Amin, Anna M. Richter

Author Affiliations +

Proceedings Volume 3590, Lasers in Surgery: Advanced Characterization, Therapeutics, and Systems IX; (1999) https://doi.org/10.1117/12.350957
Event: BiOS '99 International Biomedical Optics Symposium, 1999, San Jose, CA, United States

Abstract

Photodynamic therapy (PDT) principles were evaluated in management of benign prostatic hyperplasia (BPH) in a canine model. Five dogs were injected with benzoporphyrin derivative (BPD) and samples of prostate, bladder, urethra and rectum were taken at 1, 2, 3 and 4 hours and analyzed for BPD. Next, 16 dogs were treated with 100 Joules at 690 nm light form argon dye laser 1 hour after administration of BPD at 0.5 mg/kg using cylindrical diffuser tip fiber passed transurethrally. The prostates were harvested weekly up to 4 weeks and the size of the lesion was measured and the prostates were examined. Prostate had the highest BPD levels. Hemorrhagic lesion of 2.5 cm in diameter was noted at 1 week after PDT. At 3 and 4 weeks there were changes of glandular atrophy in the periurethral region. Minimally invasive technique of transurethral PDT causes glandular and stromal changes in the periurethral zone and has potential in the treatment of BPH.

Citation Download Citation

Sugandh D. Shetty M.D., James O. Peabody, Elsa R. Beck D.V.M., Joseph C. Cerny M.D., Mahul B. Amin, and Anna M. Richter "Transurethral photodynamic therapy in benign prostatic hyperplasia : a canine pilot study using benzoporphyrin derivative", Proc. SPIE 3590, Lasers in Surgery: Advanced Characterization, Therapeutics, and Systems IX, (22 June 1999); https://doi.org/10.1117/12.350957

ACCESS THE FULL ARTICLE

INSTITUTIONAL
Select your institution to access the SPIE Digital Library.

SELECT YOUR INSTITUTION

PERSONAL
Sign in with your SPIE account to access your personal subscriptions or to use specific features such as save to my library, sign up for alerts, save searches, etc.

PERSONAL SIGN IN

No SPIE Account? Create one

PURCHASE THIS CONTENT

SUBSCRIBE TO DIGITAL LIBRARY

50 downloads per 1-year subscription

Members: $195

Non-members: $335 ADD TO CART

25 downloads per 1 - year subscription

Members: $145

Non-members: $250 ADD TO CART

PURCHASE SINGLE ARTICLE

Includes PDF, HTML & Video, when available